 Chimerix Inc NASDAQ: CMRX has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma a most common type of brain cancer. ONC201 is an orally administered small molecule dopamine receptor D2 DRD2 antagonist and caseinolytic protease ClpP agonist. 